Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (131-140 of 238) with videos related to

Pageof 24
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 22, 2019
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administrationClemens Muehlan, Sander Brooks, Rob Zuiker, et al.
Clinical Pharmacology in Drug Development|October 26, 2022
Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT-1014-6470, a Novel Oral Complement Factor 5a Receptor 1 AntagonistAnya Hammann-Hänni, Priska Kaufmann, Gernot Klein, et al.
Journal of Clinical Pharmacology|February 28, 2002
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistJasper Dingemanse, Frederic Bodin, Erhard Weidekamm, et al.
European Journal of Clinical Pharmacology|June 23, 2017
A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjectsPierre-Eric Juif, Margaux Boehler, Yves Donazzolo, et al.
Journal of Clinical Pharmacology|February 6, 2010
Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteersS Karl Gotzkowsky, Jasper Dingemanse, Allen Lai, et al.
Diabetes Technology & Therapeutics|January 29, 2010
First-phase insulin secretion has limited impact on postprandial glycemia in subjects with type 2 diabetes: correlations between hyperglycemic glucose clamp and meal testKlaus Rave, Patricia N Sidharta, Jasper Dingemanse, et al.
Journal of Clinical Pharmacology|January 23, 2015
Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjectsMichael W Scherz, Patrick Brossard, Daniele D'Ambrosio, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 6, 2012
Determination of 6-keto prostaglandin F1α and its metabolites in human plasma by LC-MS/MSMark Enzler, Stefan Schipp, Laurent B Nicolas, et al.
Journal of Clinical Pharmacology|January 11, 2003
Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistPaul L M van Giersbergen, Gabriela Popescu, Frédéric Bodin, et al.
Frontiers in Immunology|December 28, 2020
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement PathwayMarion Anliker-Ort, Jasper Dingemanse, John van den Anker, et al.
Pageof 24

Showing results (131-140 of 238) with videos related to

Sort By:
Pageof 24
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 22, 2019
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administrationClemens Muehlan, Sander Brooks, Rob Zuiker, et al.
Clinical Pharmacology in Drug Development|October 26, 2022
Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT-1014-6470, a Novel Oral Complement Factor 5a Receptor 1 AntagonistAnya Hammann-Hänni, Priska Kaufmann, Gernot Klein, et al.
Journal of Clinical Pharmacology|February 28, 2002
Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistJasper Dingemanse, Frederic Bodin, Erhard Weidekamm, et al.
European Journal of Clinical Pharmacology|June 23, 2017
A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjectsPierre-Eric Juif, Margaux Boehler, Yves Donazzolo, et al.
Journal of Clinical Pharmacology|February 6, 2010
Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteersS Karl Gotzkowsky, Jasper Dingemanse, Allen Lai, et al.
Diabetes Technology & Therapeutics|January 29, 2010
First-phase insulin secretion has limited impact on postprandial glycemia in subjects with type 2 diabetes: correlations between hyperglycemic glucose clamp and meal testKlaus Rave, Patricia N Sidharta, Jasper Dingemanse, et al.
Journal of Clinical Pharmacology|January 23, 2015
Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjectsMichael W Scherz, Patrick Brossard, Daniele D'Ambrosio, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 6, 2012
Determination of 6-keto prostaglandin F1α and its metabolites in human plasma by LC-MS/MSMark Enzler, Stefan Schipp, Laurent B Nicolas, et al.
Journal of Clinical Pharmacology|January 11, 2003
Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistPaul L M van Giersbergen, Gabriela Popescu, Frédéric Bodin, et al.
Frontiers in Immunology|December 28, 2020
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement PathwayMarion Anliker-Ort, Jasper Dingemanse, John van den Anker, et al.
Pageof 24